Pharmacology Pharmacokinetics and Drug Metabolism Questions and Answers

Question 1

A patient is being treated with a drug that is a known substrate for the CYP3A4 enzyme.
If the patient starts taking a new medication that is a potent inducer of CYP3A4, what is the most likely pharmacokinetic consequence?

Accepted Answer

Decreased plasma concentration of the first drug, leading to potential therapeutic failure.

Answer

Increased plasma concentration of the first drug, leading to potential toxicity.

Answer

No change in the plasma concentration of the first drug.

Answer

An increase in the half-life of the first drug.

Question 2

A 500 mg dose of a drug is administered intravenously, resulting in an initial plasma concentration of 25 mg/L. What is the apparent volume of distribution (Vd) for this drug?

Accepted Answer

20 L

Answer

10 L

Answer

15 L

Answer

25 L

Question 3

Which of the following statements accurately describes Phase II metabolism?

Accepted Answer

It involves conjugation reactions that increase the water solubility of a drug for excretion. [7]

Answer

It typically involves oxidation, reduction, or hydrolysis reactions. [1, 2]

Answer

It often produces metabolites that are more pharmacologically active than the parent drug.

Answer

It is the primary mechanism of the first-pass effect.

Question 4

A patient with severe liver cirrhosis is administered a drug that is primarily eliminated through hepatic metabolism. How would this patient's condition most likely affect the drug's half-life (t1/2)?

Accepted Answer

The half-life will be significantly prolonged. [3]

Answer

The half-life will be significantly shortened.

Answer

The half-life will be unchanged.

Answer

The half-life will become dose-dependent.

Question 5

The 'first-pass effect' primarily refers to the pre-systemic metabolism of an orally administered drug that occurs in which two organs?

Accepted Answer

Liver and small intestine [13, 18]

Answer

Kidney and lungs

Answer

Stomach and spleen

Answer

Brain and heart

Question 6

Therapeutic Drug Monitoring (TDM) is most clinically useful for drugs that exhibit which of the following characteristics?

Accepted Answer

A narrow therapeutic range and significant pharmacokinetic variability. [4, 8]

Answer

A wide therapeutic index and predictable pharmacokinetics.

Answer

High protein binding and a short half-life.

Answer

Metabolism exclusively through Phase II reactions.

A patient is being treated with a drug that is a known substrate for the CYP3A4 enzyme.If the patient starts taking a new medication that is a potent inducer of CYP3A4, what is the most likely pharmacokinetic consequence?

A patient is being treated with a drug that is a known substrate for the CYP3A4 enzyme.
If the patient starts taking a new medication that is a potent inducer of CYP3A4, what is the most likely pharmacokinetic consequence?